Status:
COMPLETED
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Lead Sponsor:
Pfizer
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®. Secondary objectives: treatment response, hypothyroidism p...
Detailed Description
180 patients will be enrolled at 20 key oncological centres, the sample size is sufficient for exploratory analysis.
Eligibility Criteria
Inclusion
- Patients with advanced or metastatic renal cell carcinoma.
Exclusion
- No previous cytokines therapy.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT00684645
Start Date
June 1 2008
End Date
April 1 2011
Last Update
August 21 2012
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brno, Czechia, 625 00
2
Pfizer Investigational Site
Brno, Czechia, 656 53
3
Pfizer Investigational Site
Brno, Czechia, 656 91
4
Pfizer Investigational Site
Chomutov, Czechia, 430 12